Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair

The median survival for patients with locally advanced pancreatic cancer treated with gemcitabine and radiation is approximately one year. To develop improved treatment, we have combined a Chk1/2 targeted agent, AZD7762, currently in Phase I clinical trials, with gemcitabine and ionizing radiation i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Morgan, Meredith A., Parsels, Leslie A., Zha, Lili, Parsels, Joshua D., Davis, Mary A., Hassan, Maria C., Arumugarajah, Sankari, Hylander-Gans, Linda, Morosini, Deborah, Simeone, Diane M., Canman, Christine E., Normolle, Daniel P., Zabludoff, Sonya D., Maybaum, Jonathan, Lawrence, Theodore S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2889008/
https://ncbi.nlm.nih.gov/pubmed/20501833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3573
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller